Cohero Health company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

coherohealth.com

Founded Year

2013

Stage

Acquired | Acquired

Total Raised

$15.6M

About Cohero Health

Cohero Health empowers respiratory patients to actively engage in their own care. The company's sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. Cohero Health improves respiratory care through smart mobile devices. On November 4, 2020, Cohero Health was acquired by Aptar Pharma. The terms of the transaction were not disclosed.

Cohero Health Headquarter Location

12 E. 49th Street

New York, New York, 10017,

United States

646-926-4370

ESPs containing Cohero Health

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Patient engagement technologies facilitate communication between patients and providers. They also keep patients engaged in their own care. Solutions typically encompass a patient portal or communication platform, automated reminders, and educational tools that focus on preventive and disease-specific care.

Cohero Health named as Challenger among 4 other companies, including Wellth, Season, and Aspen RxHealth.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Cohero Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cohero Health in 1 CB Insights research brief, most recently on May 6, 2021.

Expert Collections containing Cohero Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cohero Health is included in 8 Expert Collections, including Pharma Supply Chain.

P

Pharma Supply Chain

1,357 items

V

Value-Based Care & Population Health

1,052 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

11,542 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

T

Telehealth

2,839 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

H

Health IT

11,465 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Cohero Health Patents

Cohero Health has filed 4 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/18/2018

5/17/2022

Dosage forms, Respiratory therapy, Drug delivery devices, Medical equipment, Routes of administration

Grant

Application Date

4/18/2018

Grant Date

5/17/2022

Title

Related Topics

Dosage forms, Respiratory therapy, Drug delivery devices, Medical equipment, Routes of administration

Status

Grant

Latest Cohero Health News

INVEST Pitch Perfect winner: myBiometry aims to prevent asthma attacks long before they happen

May 9, 2022

MedCity News INVEST Pitch Perfect winner: myBiometry aims to prevent asthma attacks long before they happen The startup's asthma solution, called Mya, combines home-based diagnostics, digital health and a care team to identify patients at risk and proactively intervene to prevent asthma attacks. Shares0 The novel technology at the heart of myBiometry’s asthma solution is a patented sensor (top right) and device (center) that measures nitric oxide, a biomarker of airway inflammation, in breath. This is used to determine if an individual is at risk for an asthma attack. Nationwide, more than 25 million people have asthma, including about 20 million adults and 5.1 million children and adolescents. If not well-controlled, the chronic condition can cause airways to swell and narrow, making it hard to breathe. This is called an asthma attack, and in a single year, more than 10 million people have one, according to the Centers for Disease Control and Prevention, resulting in 1.6 million emergency room visits and over 3,500 deaths. Now a Boston-based startup, myBiometry , is aiming to improve asthma management by helping people take action—even in the absence of symptoms—weeks before a potential attack could occur. “Our mission, just very simply stated, is to end asthma attacks,” said CEO Bryan Nolan, who founded the company in 2013. At the MedCity INVEST Conference in Chicago, the company was selected as the winner in the Pitch Perfect contest’s Diagnostics 2.0 track by judges, who are all active investors. Asthma and COPD is a huge market with a lot of unmet need, said Michelle Snyder, a partner at McKesson Ventures, and one of the three judges. Snyder said the company’s solution, if successful, could have a big impact not only on a patient’s quality of life but also in reducing the cost of asthma treatment to the healthcare system. In particular, myBiometry’s tech-plus approach impressed the judges. “I think in many cases, technology may not be enough,” Snyder said, and it helps to have the option to talk to a live person if a patient needs extra nudging. myBiometry’s multipronged asthma solution, called Mya, combines home-based diagnostics, digital health and a care team to identify patients at risk and proactively intervene to prevent asthma attacks, Nolan said. The novel technology at the heart of its solution is a patented sensor and device that a person with asthma can use to detect fractional exhaled nitric oxide (FeNO) in breath. This is a biomarker of airway inflammation that the company uses to help determine, among other things, if a person is at risk for having an asthma attack, said Nolan, who is the co-inventor of myBiometry’s technology. With myBiometry’s approach, you’re able track changes over time, and even before a person might be able to feel those changes, Nolan said. The inflammation in a person’s airway starts to change about 20 days before asthma symptoms or attacks—and that change can be detected by measuring the biomarker nitric oxide. “So you can pick up issues well in advance and deliver interventions to suppress the inflammation and reduce the risk,” Nolan said. Those adjustments can range from making lifestyle changes, like being active to getting more rest, to ensuring you’re taking medications appropriately. The device also gathers indoor environmental data of known asthma triggers. It connects to an app that guides the patient through the test process, which involves a slow, steady exhale into the black tip of the device. The result and its interpretation are displayed immediately after a patient performs the test once daily. “We combine this data with symptom scores, asthma control, and exposure to indoor and outdoor environmental triggers which is tracked via the app. We use the data to identify patients at risk of an attack before they become symptomatic and biologically monitor adherence and efficacy of medications,” Nolan explained. “Behind the scenes, our algorithms turn the data into personalized and actionable insights. Interventions are delivered proactively via the app or care team of certified asthma educators, nurses and physicians.” The company’s primary competitors are office and lab-based diagnostics that measure the same biomarker. It will compete against diagnostics companies like Circassia  and Cohero Health and companies that use sensors attached to inhalers to monitor adherence to asthma treatment such as Adherium  and Propeller Health , according to Nolan. “Our primary advantage is our ability to perform tests at home cost-effectively each day,” he said. “That gives us a proprietary dataset and enables us to use the trends to biologically determine adherence, the efficacy of medication, correct inhaler technique, and the risk of attack.” Data shows many people with asthma don’t use their inhalers correctly , and suffer worse outcomes as a result. Michelle Snyder at McKesson Ventures said going forward she’ll be interested to see how patients are engaging the product, and the outcomes data from using it, in terms of its impact on asthma management. “Oftentimes it’s hard to get people to change their behavior when they don’t feel like anything’s wrong,” Snyder said. But she thinks that the company’s tech-plus approach could help with that. myBiometry hasn’t commercialized its product yet, and the company didn’t provide cost or revenue projections. But it plans to sell its solution to employers. The initial target will be large, self-funded employers that already pay a subscription fee for chronic disease management programs to address conditions like diabetes and hypertension. The startup will bill monthly via invoice or claims, and the patient will need a prescription for the diagnostic but not the software. To date, the company has raised $3.3 million. It has a goal to raise another $8 million in 2022 and $10 million to $15 million in 2023, Nolan said. That will be used to fund customer pilots, submit the diagnostic for 510(k) approval, obtain regulatory clearance and begin early commercialization, he said. “Longer term our vision is really to be the leader in asthma monitoring and management,” Nolan said. “What Livongo’s been able to do in diabetes—we want to do that in asthma.” Photo: myBiometry

  • When was Cohero Health founded?

    Cohero Health was founded in 2013.

  • Where is Cohero Health's headquarters?

    Cohero Health's headquarters is located at 12 E. 49th Street, New York.

  • What is Cohero Health's latest funding round?

    Cohero Health's latest funding round is Acquired.

  • How much did Cohero Health raise?

    Cohero Health raised a total of $15.6M.

  • Who are the investors of Cohero Health?

    Investors of Cohero Health include Aptar Pharma, Paycheck Protection Program, Samsung NEXT, Omron Healthcare, Zaffre Investments and 11 more.

  • Who are Cohero Health's competitors?

    Competitors of Cohero Health include Optimize Health, Season, HealthBeacon, Sharecare, MedMinder Systems, MediSafe, Aspen RxHealth, HealthPrize Technologies, RxAnte, EveryDose and 16 more.

You May Also Like

Optimize Health Logo
Optimize Health

Optimize Health assists independent practices, group practices and ACOs, hospitals, partners, and health systems with remote patient monitoring, and engagement, client success, call center, and delivery services. The company was founded in 2015 and is based in Seattle, Washington.

MedMinder Systems Logo
MedMinder Systems

MedMinder Systems provides services that simplify medication management and improve medication adherence. The company offers a pill dispenser system that offers: patient reminders that are provided only if the meds are not taken on time (e.g. lights, beeps, phone alerts, emails, text messages); remote monitoring; immediate notifications to caregivers; data collection; and (re)filling options including manual and a pre-filled tray.

RxAnte Logo
RxAnte

RxAnte is a health care improvement company that provides a new approach for driving medication adherence by helping organizations target, manage and evaluate adherence support initiatives. By using predictive analytics, RxAnte's service helps identify the most effective outreach method to ensure that patients take medicines as directed by health care professionals. The company was founded in 2011 and is based in Portland, Maine.

EveryDose Logo
EveryDose

EveryDose provides a digital platform for health insurance companies, hospital systems, and self-insured employers to improve medication adherence using predictive analytics and personalized patient engagement.

EllieGrid Logo
EllieGrid

EllieGrid is the creator of a Smart Pillbox that enables users to organize all of their medications & vitamins in seconds, set reminders, & track history. EllieGrid can also send notifications so that users can be sure their loved ones took their medications on time.

PillDrill Logo
PillDrill

PillDrill is a smart medication tracking system that simplifies the task of everyday pill taking. It gives reminders when pills need to be taken, tracks what you're taking and how you're feeling, and keeps you connected to the people who matter most.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.